Blood advances · 2026

Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses.

СтатьяНазвание и аннотация: Перевод в очереди

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Flerlage Jamie E, Eichenauer Dennis A, Fuchs Michael, Hartmann Sylvia, Eich Hans T, Savage Kerry J, Lo Andrea C, Skinnider Brian, Akhtar Saad, Rauf M Shahzad, Maghfoor Irfan, Pinnix Chelsea C, Steiner Raphael, Milgrom Sarah A, Vega Francisco, Alomari Mohammed, Zhang Xiao-Yin, Collins Graham P, Advani Ranjana H, Kumar Priyadarshini, Dickinson Michael, Wirth Andrew, Tsang Richard, Prica Anca, Major Ajay, Smith Sonali, Hendrickson Peter G, Kelsey Christopher R, Hopkins David, McKay Pamela, Ng Andrea, Koenig Julie, Constine Louis S, Casulo Carla, Sakthivel Gukan, Baron Jonathan, Plastaras John P, Roberts Kenneth B, Gao Sarah, Al Kendi Jalila, Al Rahbi N, Balogh Alex, Levis Mario, Ricardi Umberto, Sridhar Akshay, Torka Pallawi, Specht Lena, De Silva Ravindu, Shah Nimish, Pickard Keir, Osborne Wendy, Blazin Lindsay J, Henry Michael, Chang Isabela, Smith Christine M, Halperin Daniel, Miall Fiona, Brady Jessica L, Mikhaeel George, Brennan Bernadette, Penn Anthony, Senchenko Marila A, Volchkov Egor Vasilevich, Reeves Marie, Hoppe Bradford, Terezakis Stephanie, Talaulikar Dipti, Della Pepa Roberta, Picardi Marco, Kirova Youlia, Fergusson Paige, Northend Michael, Hawkes Eliza, Lee Denise, Doo Nicole Wong, Barraclough Allison, Opat Stephen, Cheah Chan Y, Salvaris Ross, Ku Matthew, Hamad Nada, Mutsando Howard, Tedjaseputra Aditya, Gilbertson Michael, Marconi Tamara, Viiala Nicholas, Palese Monica, Shankar Ananth, Maurer Matthew J, Natkunam Yasodha, Kelly Kara M, Borchmann Peter, Hoppe Richard T, Binkley Michael Sargent

Аннотация

We evaluated outcomes by management type for patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in the Global NLPHL One Working Group retrospective database of 2243 patients with stages I to IV disease diagnosed from 1992 to 2021 at 38 international institutions. A total of 779 patients had stage IA disease with median age of 35 years (range, 3-89) and median follow-up of 6.1 years. The 6-year progression-free survival (PFS) and overall survival were 86.3% and 97.7%, respectively. Outcomes were analyzed for the 2 groups: complete resection and unresected disease. Patients with a complete resection and observation alone (n = 99) had a 6-year PFS of 65.5% vs 90.5% for those who received radiotherapy (RT) (n = 53). Patients with unresected disease (n = 627; 80.5%) had a 6-year PFS of 62.0% for rituximab alone (n = 31), 89.6% for RT alone (n = 325), 76.8% for ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) alone (n = 40), and 94.3% for ABVD plus RT (n = 130). A total of 127 patients relapsed (16.3%), of which 25 (19.7%) had transformation. Our analysis suggests the following: (1) RT improves the PFS in patients with completely resected disease; (2) rituximab or ABVD alone does not appear to achieve a durable response; and (3) chemotherapy was not observed to add additional PFS benefit when used in combination with RT. Thus, for stage IA NLPHL, RT alone is likely sufficient for definitive treatment.

Предметные рубрики MeSH

Humans Retrospective Studies Hodgkin Disease Female Neoplasm Staging Adult Male Middle Aged Adolescent Child Aged Child, Preschool Aged, 80 and over Treatment Outcome Young Adult Antineoplastic Combined Chemotherapy Protocols

Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses.

Ошибки и ограничения

Аннотация

Предметные рубрики MeSH